{"nctId":"NCT01282073","briefTitle":"Mycophenolate Mofetil in Patients With Progressive Idiopathic Membranous Nephropathy","startDateStruct":{"date":"2011-03"},"conditions":["Glomerulonephritis, Membranous"],"count":43,"armGroups":[{"label":"Mycophenolate mofetil, low dose steroid","type":"EXPERIMENTAL","interventionNames":["Drug: Mycophenolate mofetil, low dose steroid"]},{"label":"Cyclosporin, low dose steroid","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Cyclosporin, low dose steroid"]}],"interventions":[{"name":"Mycophenolate mofetil, low dose steroid","otherNames":["Myconol, MMF"]},{"name":"Cyclosporin, low dose steroid","otherNames":["Implanta soft capsule"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Patients with idiopathic membranous nephropathy\n2. The duration of disease is less than twelve months\n3. Patients with persistent proteinuria more than 8 grams per day\n4. Patients who provided informed consent\n5. The cases that satisfy more than three of following items even if proteinuria is less than 8 grams per day:\n\n   * eGFR \\< 60 ml/min/1.73m2\n   * Hypertension (BP above 140/90mmHg or BP above 120/80 in patients taking anti-hypertensive agents)\n   * 24 hours urine protein or spot urine protein/creatinine ratio \\> 5.0 g/day\n   * Serum albumin (g/dL) \\< 3.0\n   * Selectivity index \\> 0.2\n\nExclusion Criteria:\n\n1. Severe digestive organ disease\n2. Allergy history to clinical trial medication and acute or chronic allergy for 4 weeks recently.\n3. Clinical history of treatment with other immunosuppressive medication\n4. Probability of pregnancy, breast feeding woman\n5. Uncontrolled hypertension (more than 160/100mmHg)\n6. Uncontrolled systemic disease\n7. Drug addiction or alcoholics within 6 months\n8. eGFR is less than 30ml/min at screening\n9. Abnormal liver function test (more than 3 times above compared with normal value)\n10. Absolute neutrophil count \\<1,500/mm3 or leukocyte \\<2,500/mm3 or platelets \\<100,000/mm3\n11. Secondary membranous nephropathy\n12. Expected life expectancy is less than 1 year","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Complete Remission","description":"Complete remission: Reduction in proteinuria to 200 mg per day with stable serum albumin with more than 3.5 g/dL","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Partial Remission","description":"Partial remission: Reduction in proteinuria to greater than 50 percent of initial values or absolute values of proteinuria between 200 mg and 3.5 g per day","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"9","spread":null}]}]}]},{"type":"SECONDARY","title":"Estimated Glomerular Filtration Rate (eGFR)","description":"The change of eGFR mesured by Modification of Diet in Renal Disease (MDRD) study equation from baseline to 1 year after treatment","classes":[]},{"type":"SECONDARY","title":"Relapse","description":"A relapse is return of proteinuria to approximately 3.5g/day in patients who had previously undergone a complete or partial remission","classes":[]},{"type":"SECONDARY","title":"Proteinuria","description":"The change of proteinuria from baseline to 48 week after treatment","classes":[]},{"type":"SECONDARY","title":"Side Effects","description":"Any undesired effects of interventional drugs","classes":[]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":21},"commonTop":["Upper respiratory infection","Epigastric discomfort","Diarrhea","Skin infection","Anaemia"]}}}